Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 9, 2010, Pages 1688-1695

  Brepoels, Lieselot ^a   De Saint Hubert, Marijke ^a   Stroobants, Sigrid ^b   Verhoef, Gregor ^a   Balzarini, Jan ^c   Mortelmans, Luc ^a   Mottaghy, Felix M ^a,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

18F FDG PET; B cell lymphoma; Cyclophosphamide; Molecular imaging; SCID mice; Therapy response monitoring

Indexed keywords

CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DAUDI CELL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; GLYCOLYSIS; LOW DRUG DOSE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SCID MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, B-CELL; MICE; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956182982     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1479-0     Document Type: Article

References (26)

1. WA Weber 2005 Use of PET for monitoring cancer therapy and for predicting outcome J Nucl Med 46 6 983 995 1:CAS:528:DC%2BD28XitFSqtrg%3D 15937310
2. L Brepoels S Stroobants W De Wever, et al. 2007 Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria Leuk Lymphoma 48 8 1522 1530 10.1080/10428190701474365 17701583
3. L Brepoels S Stroobants W De Wever, et al. 2007 Hodgkin lymphoma: response assessment by revised International Workshop Criteria Leuk Lymphoma 48 8 1539 1547 10.1080/10428190701422414 17701585
4. K Spaepen S Stroobants P Dupont, et al. 2002 Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann Oncol 13 9 1356 1363 10.1093/annonc/mdf256 1:STN:280:DC%2BD38vjvVGjsQ%3D%3D 12196360
5. ME Juweid BD Cheson 2006 Positron-emission tomography and assessment of cancer therapy N Engl J Med 354 5 496 507 10.1056/NEJMra050276 1:CAS:528:DC%2BD28Xptlajsw%3D%3D 16452561
6. PL Zinzani V Stefoni M Tani, et al. 2009 Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma J Clin Oncol 27 11 1781 1787 10.1200/JCO.2008.16.1513 19273712
7. N Aide L Poulain M Briand, et al. 2009 Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease Eur J Nucl Med Mol Imaging 36 3 396 405 10.1007/s00259-008-0984-x 1:CAS:528: DC%2BD1MXhvF2ru7o%3D 19050878
8. L Kostakoglu SJ Goldsmith 2003 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma J Nucl Med 44 2 224 239 12571214
9. R Kubota S Yamada K Kubota K Ishiwata N Tamahashi T Ido 1992 Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography J Nucl Med 33 11 1972 1980 1:CAS:528:DyaK3sXns1aktw%3D%3D 1432158
10. K Spaepen S Stroobants P Dupont, et al. 2003 [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30 5 682 688 1:CAS:528:DC%2BD3sXjsF2ksbw%3D 12601498
11. L Brepoels S Stroobants P Vandenberghe, et al. 2007 Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy J Nucl Med 48 3 390 397 1:CAS:528:DC%2BD2sXhtVertLzJ 17332616
12. NC Krak R Boellaard OS Hoekstra JW Twisk CJ Hoekstra AA Lammertsma 2005 Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial Eur J Nucl Med Mol Imaging 32 3 294 301 10.1007/s00259-004-1566-1 15791438
13. J Leyton JR Latigo M Perumal H Dhaliwal Q He EO Aboagye 2005 Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo Cancer Res 65 10 4202 4210 10.1158/0008-5472. CAN-04-4008 1:CAS:528:DC%2BD2MXktlSmtrs%3D 15899811
14. SM Larson Y Erdi T Akhurst, et al. 1999 Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis Clin Positron Imaging 2 3 159 171 10.1016/S1095-0397(99)00016-3 14516540
15. L Kostakoglu H Agress Jr SJ Goldsmith 2003 Clinical role of FDG PET in evaluation of cancer patients Radiographics 23 2 315 340 10.1148/rg.232025705 12640150
16. A Stahl K Ott M Schwaiger WA Weber 2004 Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET Eur J Nucl Med Mol Imaging 31 11 1471 1478 10.1007/s00259-004-1626-6 1:STN:280: DC%2BD2crksV2ksg%3D%3D 15257418
17. LF de Geus-Oei HF van der Heijden EP Visser, et al. 2007 Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer J Nucl Med 48 10 1592 1598 10.2967/jnumed.107.043414 17873138
18. WA Weber V Petersen B Schmidt, et al. 2003 Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 21 14 2651 2657 10.1200/JCO.2003.12.004 1:CAS:528:DC%2BD2cXptlCktLw%3D 12860940
19. DM Euhus C Hudd MC LaRegina FE Johnson 1986 Tumor measurement in the nude mouse J Surg Oncol 31 4 229 234 10.1002/jso.2930310402 1:STN:280: DyaL283lsFGrtQ%3D%3D 3724177
20. MM Tomayko CP Reynolds 1989 Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother Pharmacol 24 3 148 154 10.1007/BF00300234 1:STN:280:DyaL1M3ovVGjug%3D%3D 2544306
21. MM Jensen JT Jorgensen T Binderup A Kjaer 2008 Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper BMC Med Imaging 8 16 10.1186/1471-2342-8-16 18925932
22. U Nestle S Kremp A Schaefer-Schuler, et al. 2005 Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer J Nucl Med 46 8 1342 1348 16085592
23. HM Zhuang A Cortes-Blanco M Pourdehnad, et al. 2001 Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun 22 10 1123 1128 10.1097/00006231-200110000-00011 1:STN:280:DC%2BD3MritVWhug%3D%3D 11567186
24. RE Meyn LC Stephens NR Hunter L Milas 1994 Induction of apoptosis in murine tumors by cyclophosphamide Cancer Chemother Pharmacol 33 5 410 414 10.1007/BF00686270 1:CAS:528:DyaK2cXls12qtrw%3D 8306415
25. VI Kaledin VP Nikolin MR Galyamova ED Vasil'eva TY Baimak NA Popova 2002 High apoptosis-inducing and antitumor activities of the products of biological but not chemical cyclophosphamide activation Dokl Biol Sci 386 426 429 10.1023/A:1020710217024 1:STN:280:DC%2BD38jht1aqsw%3D%3D 12474762
26. M Lorenzen U Wedegartner C Weber JP Petersen G Adam J Lorenzen 2005 Clinical relevance of multislice CT of the spine after osteosynthesis Rofo 177 11 1540 1544 1:STN:280:DC%2BD2MnitVOjtg%3D%3D 16302135